Morgan Stanley’s AIM ImmunoTech AIM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.4K | Buy |
50,864
+50,000
| +5,787% | +$22.8K | ﹤0.01% | 6932 |
|
|
2026
Q1 | $505 | Sell |
864
-1
| -0.1% | -$1 | ﹤0.01% | 7615 |
|
|
2025
Q4 | $976 | Buy |
865
+1
| +0.1% | +$2 | ﹤0.01% | 7375 |
|
|
2025
Q3 | $2.37K | Buy |
864
+101
| +13% | +$452 | ﹤0.01% | 7271 |
|
|
2025
Q2 | $6.59K | Sell |
763
-1
| -0.1% | -$10 | ﹤0.01% | 6957 |
|
|
2025
Q1 | $9.33K | Hold |
764
| – | – | ﹤0.01% | 6821 |
|
|
2024
Q4 | $15.1K | Sell |
764
-80
| -9% | -$1.86K | ﹤0.01% | 6656 |
|
|
2024
Q3 | $22.8K | Sell |
844
-10
| -1% | -$333 | ﹤0.01% | 6469 |
|
|
2024
Q2 | $31.8K | Hold |
854
| – | – | ﹤0.01% | 6316 |
|
|
2024
Q1 | $40.2K | Sell |
854
-694
| -45% | -$28.8K | ﹤0.01% | 6298 |
|
|
2023
Q4 | $68K | Sell |
1,548
-978
| -39% | -$45.6K | ﹤0.01% | 6288 |
|
|
2023
Q3 | $115K | Sell |
2,526
-1,834
| -42% | -$113K | ﹤0.01% | 5822 |
|
|
2023
Q2 | $292K | Sell |
4,360
-1,752
| -29% | -$84.5K | ﹤0.01% | 5472 |
|
|
2023
Q1 | $263K | Sell |
6,112
-3,064
| -33% | -$159K | ﹤0.01% | 5582 |
|
|
2022
Q4 | $286K | Sell |
9,176
-4,822
| -34% | -$224K | ﹤0.01% | 5514 |
|
|
2022
Q3 | $814K | Sell |
13,998
-2,011
| -13% | -$141K | ﹤0.01% | 5000 |
|
|
2022
Q2 | $1.25M | Sell |
16,009
-3,932
| -20% | -$377K | ﹤0.01% | 4879 |
|
|
2022
Q1 | $2.11M | Sell |
19,941
-493
| -2% | -$42.4K | ﹤0.01% | 4485 |
|
|
2021
Q4 | $1.88M | Sell |
20,434
-3,434
| -14% | -$531K | ﹤0.01% | 4636 |
|
|
2021
Q3 | $4.82M | Sell |
23,868
-1,231
| -5% | -$249K | ﹤0.01% | 3757 |
|
|
2021
Q2 | $5.39M | Buy |
25,099
+14
| +0.1% | +$3K | ﹤0.01% | 3702 |
|
|
2021
Q1 | $5.69M | Buy |
25,085
+15,087
| +151% | +$3.41M | ﹤0.01% | 3275 |
|
|
2020
Q4 | $1.79M | Buy |
9,998
+1,936
| +24% | +$387K | ﹤0.01% | 4250 |
|
|
2020
Q3 | $1.73M | Buy |
8,062
+3,294
| +69% | +$823K | ﹤0.01% | 3786 |
|
|
2020
Q2 | $1.18M | Buy |
4,768
+4,586
| +2,520% | +$1.11M | ﹤0.01% | 4046 |
|
|
2020
Q1 | $46K | Buy |
182
+181
| +18,100% | +$28.4K | ﹤0.01% | 5497 |
|
|
2019
Q4 | $0 | Sell |
1
-1,439
| -100% | -$72.2K | ﹤0.01% | 7012 |
|
|
2019
Q3 | $110K | Buy |
+1,440
| New | +$349K | ﹤0.01% | 5411 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 6971 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 6970 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7014 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7047 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 7032 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 6929 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 6931 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 6867 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6571 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6558 |
|
|
2015
Q2 | – | Sell |
-1
| Closed | -$10K | – | 7059 |
|
|
2015
Q1 | $10K | Sell |
1
-3
| -75% | -$37.5K | ﹤0.01% | 6234 |
|
|
2014
Q4 | $58K | Buy |
+4
| New | +$59.7K | ﹤0.01% | 5774 |
|
Other funds holding AIM
VF
GSC
TRCT
CA
Morgan Stanley's AIM Position: Q2 2026 in Review
Morgan Stanley increased its AIM ImmunoTech (AIM) stake by 5,787% in Q2 2026, buying an estimated $22.8K and bringing the position to 50,864 shares worth $14.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6932.
Morgan Stanley first reported a position in AIM in Q4 2014 and has held it in 30 quarters since. The position peaked at $5.69M in Q1 2021. 18 funds tracked by Wall St. Rank hold AIM as of Q2 2026.
- Morgan Stanley held 50,864 shares of AIM ImmunoTech worth $14.4K as of Q2 2026.
- Morgan Stanley bought 50,000 AIM ImmunoTech shares in Q2 2026, an estimated $22.8K.
- AIM ImmunoTech made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #6932 holding.
- Morgan Stanley first reported a position in AIM ImmunoTech in Q4 2014 and has held it in 30 quarters since.
- Morgan Stanley's AIM ImmunoTech position peaked at $5.69M in Q1 2021.
- 18 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.